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Aims: To estimate current and future direct cost of diabetes and its complications for the period 2010 and
2030.
Methods: This study is a prevalence-based approach that combines model-based forecasts of diabetes
prevalence rates from the validated OPT IMPACT Diabetes forecast model, diabetes complications
prevalence rates and health care costs and economic data. We use a societal and health care perspective
and a time horizon to 2030, and costs were estimated as international US dollar adjusted for Purchasing
Power Parity (PPP).
Results: The estimated direct costs for diabetes per person in 2012 was 1087 PPP dollars (281-1895 PPP
dollar) and the direct costs of diabetes and its complications was 2156 PPP dollar (981-4508 PPP dollar).
The estimated diabetes direct cost for the year 2012 was 184 million PPP dollar (47e320 million PPP
dollar). The cost is expected to increase to 209 million PPP dollar (54e364 million PPP dollar) in 2015,
248 million PPP dollar (64e432 million PPP dollar) in 2020 and 300 million PPP dollar (77e523 million
PPP dollar) in 3030 with 3% discounting rate assumption. The estimated direct cost of diabetes com-
plications is 365 million PPP dollar in 2012, 491 million PPP dollar in 2020 and 595 million PPP dollar in
2030.
Conclusions: The burden of diabetes and its complications on the Palestinian health system is huge and
actions are needed to address the increasing prevalence of obesity on one hand and providing proper
diabetes management on the other hand.
© 2017 Elsevier Ltd. All rights reserved.1. Introduction
Diabetes imposes a heavy health burden globally, and particu-
larly in low and middle-income countries (LMIC) like the occupied
Palestinian territory (oPt). Globally, the increase in diabetes prev-
alence is accompanied with an increase in its complication (Susan
van et al., 2010). Several studies reported the high prevalence ofd Public Health, Birzeit Uni-
rritory, Occupied Palestinian
Abu-Rmeileh), rghandour@
ataria), s.m.awawda@gmail.
M.OFlaherty@liverpool.ac.ukdiabetes and selected risk factors for the Palestinian population
(Husseini et al., 2000a, 2000b; Husseini, 2002; Abdul-Rahim et al.,
2001a, 2001b; Abdul-Rahim, 2002), and in line with most coun-
tries, the prevalence of diabetes is expected to increase in the oPt if
the current adverse major risk factors (obesity and smoking) trends
persist (Abu-Rmeileh et al., 2013). In facts, some studies showed
that obesity prevalence is increasing among Palestinian adolescents
(Mikki et al., 2009) and associated with unhealthy dietary habits
(Mikki et al., 2010).
Diabetes also exerts enormous economic pressure to the health
system and individuals because of its chronic nature and severe
complications. Global expenditure of diabetes treatment and pre-
vention exceeded 230 million USD in 2007 and is expected to
exceed 300 million USD in 2025 (van et al., 2010). In more
vulnerable economies, the health, and social impact of diabetes is
Fig. 1. Estimated diabetes prevalence for the period 2010e2030.
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more severe in the near future. A Recent review of evidence on the
economic implications of diabetes and CVD in Africa showed that
the cost of care is beyond the copy capacities of individuals, families
and governments in most African countries (Kengne et al., 2013).
This is common in other developing countries (Ramachandran
et al., 2007).
Population-based obesity interventions include healthy eating
and physical activity. Simulation model testing different in-
tercessions indicated that health information and communication
about healthy lifestyle, in addition to ﬁscal measure that includes
taxation of unhealthy food, proper labeling and restriction on
marking unhealthy diet are cost-effective and result in substantial
health gain (Cecchini et al., 2010).
The economic cost of diseases in general and speciﬁcally dia-
betes and its complications in the oPt is understudied (Younis et al.,
2015). In this study, we aim to estimate current direct cost medical
of diabetes and its complications and estimate the future cost for
the period 2010 and 2030.
2. Material and methods
This study is a prevalence-based approach that combines dia-
betes prevalence rates, diabetes complications prevalence rates and
other health care costs and cost data.
Diabetes Prevalence: The study is based on the estimated dia-
betes prevalence for the years 2010 up to 2030 with the OPT
IMPACT Diabetes Forecastmodel (Abu-Rmeileh et al., 2014). For this
study, we estimated future diabetes prevalence under two sce-
narios: A) if diabetes risk factors follow similar trends as previous
years and no intervention takes place and B) if obesity prevalence
(which is the main risk factor for diabetes in this model) reaches
certain level and stop rising as suggested by Geiss et al. (2014).
The prevalence of diabetes complications in the West Bank was
assumed to be constant overtime. Diabetes complications distri-
butions were obtained from the Palestinian Diabetes Complications
and Control Study (PDCC) conducted in Ramallah governorate
(2012) (Imseeh, 2013). These estimates were applied to the total
West Bank population to estimate the number of people with
complications (Imseeh, 2013). Diabetes complications were studied
as micro-vascular complications (neuropathy, retinopathy and ne-
phropathy) and macro-vascular complications (coronary heart
disease (CHD), cerebrovascular disease (CVA) and peripheral
vascular disease (PVD).
The cost of Diabetes and its complications: Cost data for the year
2012 was estimated based on the literature. An extensive literature
review was conducted locally, regionally and internationally to
obtain the direct medical cost estimates for diabetes and its com-
plications as deﬁned above. The search strategy included the
following keywords: cost, economic burden, cost of illness, diabetes
type II, complications, macrovascular, microvascular, direct cost,
health care expenditure. Initially, the search started in PubMed, and
then was expanded trying to ﬁnd regional data. Any study that
looked at the economic burden of diabetes and/or its complications
deﬁned as microvascular or macrovascular were included in the
analysis. Because of the shortage of local and regional costing
studies (as per our deﬁnition), mostly international costing studies
were considered. Cost data was converted to PPP and then inﬂated
to the year 2012 using cumulative country-speciﬁc inﬂation rates.
Mean, minimum and maximum costs were identiﬁed and used as
baseline estimates for the study. (Supplement 1).
Most studies included in estimating the ﬁnal cost did ingredient
costing, a bottom-up approach and were a prevalence based
studies, estimating cost per patient. The direct medical costs
included: outpatient care visits (number of physician visitsincluding GP, Dialectologist and other specialists), paramedical
visits (those include nurses, dietitian, psychotherapist, foot care,
etc), procedures, hospitalization, emergency room visits, drug use.
The cost of complications included: hospitalization, rehabilitation,
nursing, home nursing, outpatient therapy, physician visits, diag-
nostic and therapeutic procedures such as CABG, PTCA, coronary
angiography, Home health care, cardiac rehabilitation.
Using these cost estimates and diabetes population in the West
Bank, cost per patent for each subgroup was estimated.
Sensitivity analysis: The baseline cost data for this study
depended on estimated costs from different countries and on
different time frames. Therefore, we conducted a sensitivity anal-
ysis with minimum and maximum costs.
3. Results
3.1. Diabetes prevalence
The prevalence of diabetes mellitus in the year 2010 was 15.3%
and is expected to increase to 19.7% in 2017, 21.2% in 2020, 22.8% in
2025 and 23.4% in 2030 (Fig. 1). If the prevalence of obesity reached
a natural plateau in 5 years as observed in the USA between 1980
and 2012, then the prevalence of diabetes mellitus is expected to
reach 21.2% in 2020, 22.3% in 2025 and 22.5% in 2030.
3.2. The direct cost of diabetes
Based on the cost obtained from several studies, the estimated
direct cost for diabetes per person in 2012 was 1146 USD
(392e2336 USD) while the estimated direct cost for diabetes and
its complications was 2056 USD (1411e3109 UDS). Table 1 presents
all estimated costs for diabetes and its complications.
Table 2 shows the predicted diabetes and diabetes complica-
tions direct cost for the period 2012 up to 2030 accounting for 3%,
5% and 7% discounting rates. The estimated diabetes direct cost
(without complications) for the year 2012 was 194 million USD
(66e395 million USD). If no national intervention was taken by the
governorate, the cost is expected to increase to 220 million
(75e449 millions) in 2015, 261 million (89e532 millions) in 2020
and 316 million (108e644 millions) in 2030 with 3% discounting
rate assumption.
Diabetes direct cost is estimated to take 11.9%e15.4% of the Total
Health Expenditure in the period 2012e2030 (Table 3).
If obesity prevalence level off by the year 2017, the estimated
Table 1
The estimated direct cost of diabetes and its complications per person for the year
2012.
Direct cost of diabetes only Direct cost of diabetes & complications
Mean $ 1146 $ 2056
Min $ 392 $ 1411
Max $ 2336 $ 3109
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2020, and 304 million (104e620 millions) in 2030 with a 3% dis-
counting rate assumption (Table 2). Diabetes direct cost is esti-
mated to take 11.5e15.4 of the Total Health Expenditure in the
period 2012e2030 if obesity prevalence levels off in 2017 (Table 3).
The estimated cost increase dramatically when diabetes com-
plications are included. The estimated direct cost of diabetes
complications is 348 million in 2012, 469 million in 2020 and 567
million in 2030 if no intervention takes place (Table 2). If the
prevalence of obesity stopped increases (if action is taken) in 2017,
the estimated direct cost for diabetes and its complication almost
drop by half. Consequently, the mean of the cost decrease when the
discounting increase.
4. Discussion
Future trends of diabetes prevalence will have a profound
impact on oPt health care budget and economy. The direct medicalTable 2
The estimated direct cost of diabetes and its complications with 3%, 5% and 7% discount
Year Direct cost of diabetes only
Mean Min Max
No Intervention
3% discounting
2012 194,052,122 66,377,340 395,554,761
2015 220,178,161 75,313,996 448,809,935
2020 261,239,284 89,359,336 532,508,698
2025 293,453,763 100,378,600 598,174,512
2030 316,356,255 108,212,611 644,858,823
5% discounting
2012 190,355,891 65,113,010 388,020,385
2015 203,875,924 69,737,664 415,579,546
2020 219,720,114 75,157,317 447,876,254
2025 224,187,112 76,685,295 456,981,757
2030 219,526,530 75,091,099 447,481,653
7% discounting
2012 186,797,837 63,895,944 380,767,667
2015 189,054,940 64,668,007 385,368,533
2020 185,404,174 63,419,229 377,926,834
2025 172,142,435 58,882,927 350,894,178
2030 153,388,189 52,467,862 312,665,627
Natural Intervention
3% discounting
2012 194,052,122 66,377,340 395,554,761
2015 220,178,161 75,313,996 448,809,935
2020 260,243,116 89,018,588 530,478,114
2025 286,614,869 98,039,292 584,234,149
2030 304,421,728 104,130,294 620,531,549
5% discounting
2012 190,355,891 65,113,010 388,020,385
2015 203,875,924 69,737,664 415,579,546
2020 218,882,268 74,870,724 446,168,393
2025 218,962,467 74,898,156 446,331,869
2030 211,244,900 72,258,290 430,600,425
7% discounting
2012 186,797,837 63,895,944 380,767,667
2015 189,054,940 64,668,007 385,368,533
2020 184,697,184 63,177,396 376,485,708
2025 168,130,683 57,510,670 342,716,644
2030 147,601,625 50,488,514 300,870,329cost for diabetes is expected to increase by 1.6 folds between 2012
and 2030.A similar increase in direct medical cost was reported for
China and Canada (Seuring et al., 2015). In 2030, between 567 USD
(if obesity prevalence continues to increase)and 347 USD (if obesity
prevalence stopped increasing) will be spent in tackling the obesity
and diabetes epidemic, resulting in 20% total expenditure. This is
clearly unsustainable since Health Expenditure is only 11% of GDP
and 41% of the total health expenditure is out of pocket.
The study estimates the direct cost of diabetes and its compli-
cations using two scenarios: the ﬁrst estimates the costs of diabetes
if the current trends of diabetes risk factors remain the same with
no intervention taking place. The second scenario estimates the
costs when one of diabetes risk factors, obesity prevalence, reaches
a saturation level and stop to increase as so called natural inter-
vention. The differences in costs between the two scenarios are
dramatic which highlight the importance of adopting population-
based intervention targeting obesity. These scenarios were
applied to estimate both the cost of diabetes alone and the cost of
diabetes and its complications combined. The cost triples when
diabetes complications are included in both scenarios.
Strengths: This study is using future prevalence estimates using
a validated model. OPT IMPACT Diabetes Forecast model which was
validated in several Arab countries and Turkey (Saidi et al., 2015; Al
Ali et al., 2013; S€ozmen et al., 2015). Further, because we are using
cost estimates based on international and regional Literature, we
presented the results with sensitivity analysis using the minimuming rates.
Direct cost of diabetes & complications
Mean Min Max
348,142,375 238,924,558 526,446,812
395,014,223 271,091,960 597,324,523
468,680,601 321,648,019 708,719,838
526,475,512 361,311,745 796,114,965
567,564,101 389,510,188 858,247,467
341,511,092 234,373,614 516,419,253
365,766,929 251,020,008 553,097,949
394,192,456 270,527,994 596,081,880
402,206,546 276,027,936 608,200,463
393,845,153 270,289,646 595,556,703
335,127,707 229,992,799 506,766,557
339,177,099 232,771,832 512,889,884
332,627,385 228,276,868 502,985,671
308,834,944 211,948,495 467,007,705
275,188,583 188,857,534 416,129,039
154,222,676 105,840,562 233,209,289
180,119,813 123,613,354 272,369,893
235,021,180 161,291,286 355,389,517
293,927,680 201,717,878 444,465,543
347,412,544 238,423,687 525,343,191
151,285,101 103,824,551 228,767,208
166,783,541 114,460,884 252,203,322
197,668,894 135,657,009 298,906,903
224,549,165 154,104,510 339,554,161
241,077,169 165,447,415 364,547,139
148,457,342 101,883,905 224,491,185
154,659,028 106,140,024 233,869,123
166,796,919 114,470,065 252,223,552
172,420,438 118,329,396 260,727,209
168,446,111 115,601,879 254,717,393
Table 3
The percentage of diabetes cost out of Total Health Expenditure.
Year Direct cost of diabetes
out of THE
Direct cost of diabetes &
complications out of THE
Mean Min Max Mean Min Max
3% discounting
2012 15.4% 5.3% 31.3% 27.6% 18.9% 41.7%
2015 15.3% 5.2% 31.1% 27.4% 18.8% 41.4%
2020 14.1% 4.8% 28.8% 25.4% 17.4% 38.4%
2025 13.0% 4.5% 26.6% 23.4% 16.1% 35.4%
2030 11.9% 4.1% 24.3% 21.4% 14.7% 32.4%
5% discounting
2012 15.1% 5.2% 30.7% 27.1% 18.6% 40.9%
2015 14.1% 4.8% 28.8% 25.3% 17.4% 38.3%
2020 11.9% 4.1% 24.3% 21.3% 14.7% 32.3%
2025 10.0% 3.4% 20.3% 17.9% 12.3% 27.0%
2030 8.3% 2.8% 16.9% 14.8% 10.2% 22.5%
7% discounting
2012 14.8% 5.1% 30.2% 26.6% 18.2% 40.2%
2015 13.1% 4.5% 26.7% 23.5% 16.1% 35.5%
2020 10.0% 3.4% 20.5% 18.0% 12.4% 27.2%
2025 7.7% 2.6% 15.6% 13.7% 9.4% 20.8%
2030 5.8% 2.0% 11.8% 10.4% 7.1% 15.7%
Natural intervention Mean Min Max Mean Min Max
3% discounting
2012 15.4% 5.3% 31.3% 12.2% 8.4% 18.5%
2015 15.3% 5.2% 31.1% 12.5% 8.6% 18.9%
2020 14.1% 4.8% 28.7% 12.7% 8.7% 19.2%
2025 12.7% 4.4% 26.0% 13.1% 9.0% 19.8%
2030 11.5% 3.9% 23.4% 13.1% 9.0% 19.8%
5% discounting
2012 15.1% 5.2% 30.7% 12.0% 8.2% 18.1%
2015 14.1% 4.8% 28.8% 11.6% 7.9% 17.5%
2020 11.9% 4.1% 24.2% 10.7% 7.3% 16.2%
2025 9.7% 3.3% 19.8% 10.0% 6.9% 15.1%
2030 8.0% 2.7% 16.2% 9.1% 6.2% 13.7%
7% discounting
2012 14.8% 5.1% 30.2% 11.8% 8.1% 17.8%
2015 13.1% 4.5% 26.7% 10.7% 7.4% 16.2%
2020 10.0% 3.4% 20.4% 9.0% 6.2% 13.7%
2025 7.5% 2.6% 15.2% 7.7% 5.3% 11.6%
2030 5.6% 1.9% 11.3% 6.4% 4.4% 9.6%
N.M.E. Abu-Rmeileh et al. / Obesity Medicine 6 (2017) 18e22 21and maximum cost estimates. With these estimates we take into
account the literature variations.4.1. Limitations
As in any study, our analyses have limitations the direct costs
were obtained from the literature. Whereas this data sources could
not entirely be transferable to the oPt setting, it nonetheless pro-
vides a set of costs estimates that is grounded in empirical data
from similar countries, providing estimates that can be critically
appraised by policy makers more explicitly. Furthermore, our
extensive sensitivity analysis effectively maps this uncertainty,
providing useful boundaries for the future economic burden of
diabetes in the oPt.
A further difﬁculty is the accurate estimation of indirect and
intangible costs from a societal perspective which are inherently
difﬁcult and costly tomeasure accurately. This includes the effect of
diabetes on patient's ability to continueworking as effective as they
used to before the onset of the disease, sickness, absence, disability,
premature retirement or premature mortality (Ettaro et al., 2004;
Tharkar et al., 2010). The last component of diabetes costs is the
intangible costs which include pain, anxiety inconvenience and
other factors that decrease the quality of life. However, even taking
into account the huge uncertainty, our results were robust in the
sensitivity analysis.4.2. Public health implications
There should be quick prevention and intervention actions.
Primary prevention to protect people from developing diabetes
through targeting diabetes risk factors and try to slow down or stop
the increasing prevalence of obesity and smoking. The emphasis
should be on obesity structural interventions that prove to be cost
saving. Such intervention may include reduce sugar intake through
ﬁscal measures, improve nutrition through reformulation and
regulation, facilitate physical activity through built environment,
health promotion and education. Special attention should be given
to susceptible individuals though lifestyle modiﬁcation in-
terventions (World Health Organization, 2013). As obesity pre-
vention is key to prevent diabetes, additional gains from other
diseases associated to obesity, including CVD, some cancers and
musculoskeletal disease will make any investment in obesity pre-
vention likely to be cost-effective if not cost-saving (Cecchini et al.,
2010).
The World Health Organisation has proposed the best buys to
reduce the burden of the Non-communicable diseases in general
(World Health Organisation, 2011). Such cost eeffective in-
terventions need to be further evaluated and select which is best for
the Palestinian context given its speciﬁc limited resources. Though
none is completely adopted by policy makers, there are sporadic
efforts. For example, the Palestinian Public Health Law includes few
items that regulate tobacco. These items focus mainly on selling
and advertising tobacco products. Still, it is missing the bylaws and
it is not well implemented (Husseini et al., 2009).
Again, addressing NCDs and their risk factors requires a multi-
disciplinary action by all stakeholders including the government,
civil society, development agencies, private sector and academia.
All can provide the proper leadership, create infrastructure, set
health polices, provide scientiﬁc evidence and expertise, and sup-
port implementation and action on the ground.
This study illustrates the huge burden of diabetes and its
complication on the Palestinian health system. The prevalence of
diabetes mellitus in the West Bank of the Occupied Palestinian
territory is high and is expected to increase in the near future and
thus estimates of current and future direct cost of diabetes and its
complications can assist decision-makers understand the magni-
tude of the problem, and plan resource allocation and help priori-
tize interventions.
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